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Abstract. The wide availability of high bandwidth public wireless networks as 
well as the miniaturisation of medical sensors and network access hardware 
allows the development of advanced ambulant patient monitoring systems. The 
MobiHealth project developed a complete system and service that allows the 
continuous monitoring of vital signals and their transmission to the health care 
institutes in real time using GPRS and UMTS networks. The MobiHealth system 
is based on the concept of a Body Area Network (BAN) allowing high 
personalization of the monitored signals and thus adaptation to different classes of 
patients. The system and service has been trialed in four European countries and 
for different patient cases.  First results confirm the usefulness of the system and 
the advantages it offers to patients and medical personnel.  
1 Introduction 
In the next few years the expansion and availability of high bandwidth wireless networks, like 
GPRS and UMTS, combined with the ever-advancing miniaturization of sensor devices and 
computers, will give rise to new services and applications that will affect and change the daily 
life of citizens. An area where these new technological advances will have a major effect is 
health care. Citizens, being patients or non-patients, will to not only be able get medical advice 
from a distance but will also be able to send from any location full, detailed and accurate vital 
signal measurements, as if they had been taken in a medical center, implementing what we can 
call “ubiquitous medical care”. 
Towards this direction different initiatives, projects and prototypes were developed in 
the past few years ranging from stand-alone devices measuring and storing one specific vital 
sign (like insulin level) to chest bands measuring heart and blood parameters and easy to wear 
t-shirts with woven sensors. However all these devices are not linked with any specific service 
and do not provide sufficient flexibility for personalization. The device collects the vital signal 
data and brings to the medical expert for post-processing; no direct, on-line connection being 
available. On the other hand the devices that do transmit the vital signal measurements, only 
transmit a fixed small number of vital signals (one or two) without any possibility for 
expansion. Furthermore, these devices cannot be personalized, by adding for example a 
specialized sensor for a specific patient. 
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The MobiHealth project’s target was to provide a solution that does not suffer from the 
above limitations. The project, started in May 2002 and completed in February 2004, has 
indeed developed a system and a service for ambulant patient monitoring over public wireless 
networks. Based on a body area network interconnecting different vital signal sensors and 
actuators, the measurements are transmitted using UMTS[1] (or GPRS) to the health care 
center where they are presented life to the medical personnel. This way patients can be 
continuously monitored and receive advice when needed. In the last months of the project 9 
different trials scenarios were implemented for different types of patients. These trials allowed 
us to identify problems and issues in the development of mobile e-health services and identify 
limitations and shortcomings of the existing and forthcoming public network infrastructure. 
The use of GPRS and UMTS as communication technology is essential due to the need 
to support a continuous connection to the healthcare center, the high bandwidth required for the 
transmission of the data (which can easily reach the level of 100 Kbps), the communication 
costs involved (in GPRS and UMTS, the cost is calculated per Kb, instead of per minute of 
connection) and the high quality of service required for all health related applications. These 
are requirements that cannot be met with current GSM technology. In fact the overall goal of 
MobiHealth was to evaluate the ability of 2.5 and 3G communication technologies to support 
innovative mobile health services. The main output of the project therefore is an assessment of 
the suitability of GPRS and UMTS to support such services. In addition the project delivered 
an architecture for, and a prototype of, a health BAN and a generic m-health service platform 
for provision of ubiquitous healthcare services based on Body Area Networks.  
In this paper we present the developed MobiHealth system and service, give an 
overview of the trials performed and discuss the issues and limitations related to the 
deployment of 2.5/3G networks in the support of mobile health care services. Section 2 
presents an overview of the different systems available today, discussing briefly their 
advantages and disadvantages, section 3 presents an overview of the MobiHealth architecture 
while section 4 describes the performed trials. Finally section 5 presents the evaluation 
methodology and the first results of the trials’ evaluation and section 6 our conclusions and 
future directions.  
2 Issues Related to Mobile Health Care Monitoring Systems 
The need for a cost reduction in health care expenses as well as the demand from patients for 
ubiquitous health care provision (health care available anywhere at any time) boosted the 
research and the development of different types of wearable and mobile health care systems 
and devices. While simple vital signal measuring devices, like for example chest band for 
training and portable glucose control devices, have been available in the market for many 
years, it is only during the last few years that wearable and mobile sensors became sufficiently 
advanced, diverse and low cost, able to provide measurement in a quality comparable to 
laboratory measurements. Combined with the miniaturization of computers and 
communications hardware different wearable health care devices were developed and some are 
already available in the market. 
The systems available today in the market or under development can be classified in 
different ways, depending on their capabilities and target use. A first element is the number of 
vital signal sensors that are or can be supported by the device/system. At the lower end we find 
specialized devices measuring only one signal, like glucose or heart rate, like the Glucowatch 
of Sankyo Pharma and Cygnus [2] measuring the glucose level for diabetics. In the middle we 
have closed systems that are able to measure a predefined set of vital signals, like the lifeshirt 
of Vivometrics [3] and VTAM from Medes [4], while at the high end we have devices that are 
configurable allowing the integration of an arbitrary number of sensors, like the MobiHealth 
system [5]. 
The second element to consider in a classification is the handling of the measurement 
data. We have from one side devices that collect the measurement data, store them locally and 
the user must transfer the collected measurements off-line to the health broker where they are 
post-processed. An important aspect is the quantity of data that can be stored, expressed in 
minutes or hours of measurements. On the other side we have devices and systems that 
transmit the data on-line, using a wireless connection, to the health broker. The important 
issues are the capacity (bandwidth available) of the network and the coverage area (short range 
in-house or use of public wireless networks). 
A third element is the simplicity of use and wearability of the sensors. We have systems 
where the sensors are integrated in a T-shirt or a wrist watch-like device, systems where the 
sensors are independed devices linked wirelessly or wired to a small processing device and 
implantable sensors that are permanently attached to the patient. 
Other issues that define the usability and functionality of an ambulant monitoring 
system are its autonomy, the accuracy of the measurements and the integrated medical 
analysis. The system autonomy depends on its power consumption (which is high for systems 
that transmit data using a wireless connection), while the accuracy of measurement depends on 
the type of sensors used (for example dry ECG sensors versus “standard” ones) and the 
algorithms that eliminate artefacts due to movement of the user. 
3 The MobiHealth System 
The MobiHealth system provides a complete end-to-end e-health platform for ambulant patient 
monitoring, deployed over UMTS and GPRS networks. The MobiHealth patient/user is 
equipped with different vital constant sensors, like blood pressure, pulse rate and ECG 
interconnected via the healthcare Body Area Network (BAN). The Mobile Base Unit (MBU) is 
the central point of the healthcare BAN, aggregating the vital sensor measurements and 
transmitting them via UMTS or GPRS to the back-end system, which can be located within the 
health broker premises or be part of a wireless service provider. From there the measurements 
are dispatched to the health care broker where the medical personnel monitor them. It must be 
noted that automated monitoring and patient feedback is currently not supported by the 
MobiHealth system, as this was outside the scope of the project. 
3.1 The Healthcare BAN architecture 
The concept of the Body Area Network originally came from IBM[6] and was developed 
further by many other researchers, for example at Philips [7], at the University of Twente [8], 
and at Fraunhofer [9]. In the Wireless World Research Forum’s Book of Visions, we define a 
BAN as “a collection of (inter) communicating devices which are worn on the body, providing 
an integrated set of personalised services to the user”[10]. In the context of the MobiHealth 
project the Healthcare BAN is a health monitoring tool that consists of sensors, actuators, 
communication and processing facilities connected via a wireless network which is worn on 
the body and which moves around with the person (i.e., the BAN is the unit of roaming). 
We call communication between entities within a BAN intra-BAN communication. To 
allow external communication of the BAN for remote monitoring we use a gateway, the 
Mobile Base Unit (MBU), which provides the extra-BAN communication. Figure 1 shows the 
architecture of a healthcare BAN. Sensors and actuators establish an ad-hoc network and use 
the MBU to communicate outside the BAN. The MBU could also be implemented as a sensor 
















Figure 1 Healthcare BAN architecture 
Intra-BAN communication is based on wireless networks like Bluetooth[11] and 
Zigbee[12], while the extra-BAN communications is done via GPRS and UMTS.1 
A sensor is responsible for the data acquisition process, ensuring that a physical 
phenomenon, such as patient movement, muscle activity or blood flow, is first converted to an 
electrical signal, which is then amplified, conditioned, digitised and communicated within the 
BAN. 
The Healthcare BAN sensors can be self-supporting and/or front-end supported. Self-
supporting sensors have a power supply and facilities for amplification, conditioning, 
digitisation and communication. Self-supporting sensors are independent building blocks of a 
BAN and ensure a highly configurable healthcare BAN. However, each sensor runs at its own 
internal clock and may have a different sample frequency. Consequently, mechanisms for the 
synchronization between sensors may be needed. 
Front-end supported sensors share a common power supply and data acquisition 
facilities. Consequently, front-end supported sensors typically operate on the same front-end 
clock and jointly provide multiplexed sensor samples as a single data block. This avoids the 
need for synchronization between sensors.  
3.2 Service platform architecture 
Collecting and transmitting the vital signal measurements is only part of the healthcare service 
developed in the MobiHealth project. The Healthcare BAN is only one part of a service 
platform that integrates the mobile part (healthcare BAN) and the health broker resident 
system. Figure 2 shows the overall functional architecture of the MobiHealth service platform. 
The dotted square boxes indicate the physical location where parts of the service platform are 
                                                 
1 WLAN was also used in the initial stages of the project for testing purposes. 
executing. The rounded boxes represent the functional layers of the architecture. The M-health 
service platform consists of sensor and actuator services, intra-BAN and extra-BAN 
communication providers and an M-health service layer. The intra-BAN and extra-BAN 
communication providers represent the communication services offered by intra-BAN 
communication networks (e.g. Bluetooth) and extra-BAN communication networks (e.g. 
UMTS), respectively. The M-health service layer integrates and adds value to the intra-BAN 
and extra-BAN communication providers. The M-health service layer masks applications from 
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Figure 2 Service platform functional architecture 
 
Applications that run on top of the service platform can either be deployed on the MBU 
(for on-site use e.g. by a visiting nurse) or on the servers or workstations of the healthcare 
provider, i.e. the call centre or the co-located secondary care centre in Figure 2. For this the M-
health service platform offers a number of services including: 
 
o BAN registration: the service platform maintains a list of active BANs and allows 
applications to retrieve the specific configuration of a BAN.  
o BAN discovery: applications can subscribe to the platform to receive a notification in case a 
BAN becomes active (i.e. a patient switches on a BAN). 
o BAN authorization and authentication: the service platform authenticates BANs and only 
allows authorized BANs to convey data.  
o BAN data encryption: the platform encrypts data that is conveyed over unsecured networks 
o BAN configuration: the service platform allows online configuration and management of 
the BANs, such as (de)activation of specific sensors or modification of the sample 
frequency of a sensor. 
o Data acquisition control: the service platform enables applications to start, stop or 
temporarily interrupt the data acquisition process of a BAN. 
o Query and modify actuator status: applications can manipulate actuators from a distance. 
o BAN data storage: the service platform can act as an intermediate storage provider to 
applications. Applications determine the minimal duration of the storage. 
o BAN data monitoring: the service platform can apply filtering algorithms on the BAN data 
to determine if an interesting event has taken place (e.g. a patient has dropped on the floor) 
and report this event to the application layer.  
 
A refined view of the M-Health service layer is shown in Figure 3 for the case where 
the M-health service platform user (e.g. at a hospital) is located remotely from the call centre. 
The arrows in the figure show the flow of the BAN data. The BANip entity is a protocol entity 
for the BAN interconnect protocol [13]. Peer entities can be found on the MBU and on the 
computing infrastructure (in the ‘fixed’ network). The BANip entities communicate through a 







     
     

















Figure 3 Refined view of the service platform 
 
The surrogate component uses the BANip protocol to obtain BAN data. This 
component contains a representation of the BAN (i.e. the surrogate) and shields other 
components in the ‘fixed’ network from the BANip and direct interaction with the BAN. The 
surrogate component can be accessed by any application protocol, including Remote Method 
Invocation (RMI) as depicted in Figure 3. The storage entity uses RMI to interact with the 
surrogate as if it interacts with the remote BAN at the location of the patient, without the 
burden of the discovery, registration and authentication of the BANs. The surrogate component 
is therefore the intermediary whereto BAN data from the location of the patient is pushed and 
wherefrom the data is pulled by the application component residing at the secondary care 
centre. The storage entity provides the BAN data storage service to the application layer. 
Configuration, discovery and monitoring services are offered as separate entities, with the 
same structure as the storage entity.  
Applications that use the m-health service layer can range from simple viewer 
applications that provide a graphical display of the BAN data, to complicated applications that 
analyse the data.  
3.3 Service platform technical requirements 
To leverage the healthcare BAN for use as a remote monitoring tool several issues and 
considerations were taken into account in the design and development of the supporting 
healthcare service platform. These issues reflect both commercial and social needs or 
restrictions, as well as technical limitations of underlying infrastructures [16]. The most 
important ones being scalability, security and extra-BAN network restrictions. 
The healthcare service platform must be able to support services that cover niche 
healthcare cases that require the simultaneous monitoring of small numbers of patients (e.g., 
ranging from 10 to 100 BANs) to large-scale chronic disease management processes (e.g., 
100.000+ BANs used to monitor COPD patients). In addition geographical scalability, that is 
global coverage, should be supported. 
The healthcare service platform connects the BAN with the Internet. Consequently, the 
BAN is subject to attacks from malicious Internet users who either try to break into the system 
or frustrate its use. Therefore the healthcare service platform should be protected from attacks 
like Denial of Service (DoS). Mechanisms that ensure data integrity must be included to 
prevent corruption of BAN data. Each BAN should authenticate itself with the service 
platform, which should only allow authorized BANs to send BAN data. 
Traditionally, providers of data (such as web servers) are deployed on a computing 
infrastructure with sufficient network and processing capacity. Consumers of data (such as web 
browsers) assume that providers are available most of the time (except for maintenance) and 
have sufficient bandwidth to serve a reasonable amount of consumers. This model was the one 
adopted by the public wireless network operators where the data consumer, i.e., the mobile 
device, initiates a network connection to the producer. Based on this assumption, most network 
operators of 2.5/3G networks hand out private space IP addresses to mobile devices. 
Connection establishment initiated from a fixed host on the public Internet to a mobile device 
is therefore inhibited.  
However in the MobiHealth system each BAN is a data producer. For the service 
platform, the producer and consumer roles are thus inverted because the provider of data is 
deployed on a mobile device (i.e. the MBU) while the consumer of data is deployed on a fixed 
host with sufficient processing and communication capacity. The MBU may be temporary 
unavailable, due to the short life-time of batteries or because it has moved to an area without 
coverage of the public wireless infrastructure. The service platform therefore masks the 
inversion of the producer-consumer roles from the BAN and the end-users (e.g., a patient 
wearing the BAN or a medical specialist analyzing the BAN data). 
3.4 Implementation details  
The Healthcare BAN has been implemented using both front-end supported and self-
supporting sensors. Figure 4 shows the self-supporting EISlab sensor [13] (left) and a TMSI 
front-end (right). Both approaches use Bluetooth for intra-BAN communication. The front-end 
also allows ZigBee as an alternative intra-BAN communication technology.  Electrodes, a 
movement sensor, a pulse oximeter and an alarm button are examples of sensing devices that 
can be attached to the front-end. 
The MBU was implemented on an iPAQ H3870. This device has built-in Bluetooth 
capabilities and can be extended with a GPRS jacket. Figure 5 shows a picture of the MBU that 
also runs a viewer application. 
The BANip has been implemented using Java 2 Micro Edition (J2ME)[15]. The BANip 
is implemented on the MBU as an HTTP client that collects a number of samples into the 
payload of an HTTP POST request and invokes the post on the surrogate. We’ve used a 
standard HTTP proxy to act as a security gateway of the surrogate. In case the surrogate needs 
to control the MBU, these control commands are carried as payload of the HTTP reply. 
The surrogate has been implemented using the Jini Surrogate architecture[16]. Jini 
provides the implementation for auto-discovery and registration of the BAN. In terms of the 
Jini architecture the surrogate is a service provider. Other components, such as the BAN data 
storage component, are service users from the perspective of the surrogate. 
 
 
Figure 4 Self supporting sensor and a front-end Figure 5 iPAQ H3870 acts as MBU 
4 The MobiHealth Trials 
The primary question addressed by the MobiHealth project was whether 2.5/3G 
communications technologies can support the MobiHealth vision, i.e., enable the move towards 
empowered managed care based on mobile health care systems. To obtain an (as much as 
possible) valid reply to this question, we organized and conducted nine different trials in four 
different countries around Europe, expecting that for some trials the existing infrastructure will 
be adequate while for others it may be insufficient. We must note however that the conducted 
trials were not clinical trials. The primary target of the project being the evaluation of the 
2.5/3G infrastructures and not the validation of new medical tools and processes. 
The trials also provide us the basis for a market validation of the system and service, 
towards further commercialisation. They are targeted at the areas of acute (trauma) care, 
chronic and high-risk patient monitoring and monitoring of patients in home-care settings. The 
trials cover a range of conditions including pregnancy, trauma, cardiology (ventricular 
arrhythmia), rheumatoid arthritis and respiratory insufficiency (chronic obstructive pulmonary 
disease), covering both use of patient BANs and health professional BANs (nurse BAN, 
paramedic BAN). The trials were selected to represent a range of bandwidth requirements: low 
(less than 12 Kbps), medium (12 – 24 Kbps) and high (greater than 24 Kbps) and to include 
both non-real time (like routine transmission of tri-weekly ECG) and real time requirements 
(e.g. alarms, transmission of vital signs in a critical trauma situation). For each application the 
generic MobiHealth BAN is specialized by addition of the appropriate sensor set and 
corresponding application software. 
4.1 Trial 1 - Germany  
Telemonitoring of patients with cardiac arrhythmia 
The target group in this trial are patients with ventricular arrhythmia who are undergoing drug 
therapy. Cardiac arrhythmia is very common and in many cases is related to coronary heart 
disease. Around one million patients suffer from coronary heart disease in Germany today. In 
patients suffering from arrhythmia, ECG measurements have to be taken regularly to monitor 
the efficacy of drug therapy. In order to save time and reduce costs, the patient is able to 
transmit ECG and blood pressure via GPRS from home or elsewhere to the health call centre, 
where the vital signs are monitored by a cardiologist. The intention is that irregular patterns in 
these vital signs will be detected quickly and appropriate intervention can be initiated. This 
trial is to evaluate how both patients and the cardiologist gain time and cost advantages, as well 
as to document processes for implementation. 
4.2 Trial 2 - The Netherlands  
Integrated homecare for women with high-risk pregnancies 
The trial will use the MobiHealth BAN to support integrated homecare for women with high-
risk pregnancies. Women with high-risk pregnancies are often admitted to the hospital for 
longer periods of time because of possible pregnancy-related complications. Admission is 
necessary for the intensive monitoring of the patient and the unborn child. Homecare with 
continuous monitoring is desirable and can postpone hospitalisation and reduce costs, as well 
as offering more security for the mother and unborn child. In this trial, patients are monitored 
from home using the MobiHealth BAN and the (maternal and foetal) biosignals are transmitted 
to the hospital. An additional objective of the trial is to evaluate if such a solution postpones 
hospitalisation and reduces costs. 
4.3 Trial 3 - The Netherlands  
Tele trauma team  
MobiHealth BANs will be used in trauma care both for patients and for health professionals 
(ambulance paramedics). The trauma patient BAN will measure vital signs which will be 
transmitted from the scene to the members of the trauma team located at the hospital. The 
paramedics wear trauma team BANs which incorporate a video camera, an audio system and a 
wireless communication link to the hospital. The purpose of this trial is to evaluate whether use 
of mobile communications can improve quality of care and decrease lag-time between the 
accident and the intervention. When using telemetry technology, time can be saved and thus 
treatment and chances for patient recovery improved. Faster intervention is expected to 
increase survival rates and decrease morbidity. Parameters to be measured are breathing 
frequency, oxygen saturation, pulse rate, blood pressure, pupil size and reactions and amount 
of fluids infused. Video from the scene will be transmitted assuming UMTS availability. 
4.4 Trial 4 - Spain 
Support of home-based healthcare services 
This trial involves use of GPRS for supporting home-based care for elderly and chronically ill 
patients including remote assistance if needed. Patients suffer from co-morbidities including 
COPD. The MobiHealth nurse-BAN will be used to perform patient measurements during 
nurse home visits and the MobiHealth patient-BAN will be used for continuous monitoring 
during patient rehabilitation at home, or even outdoors. It is very important to facilitate 
patients' access to healthcare professionals without saturating the available resources, and this 
is one of main expected outcomes of the MobiHealth remote monitoring approach. Parameters 
to be measured are oxygen saturation, ECG, spirometry, temperature, glucose and blood 
pressure. 
4.5 Trial 5 - Spain  
Outdoor patient rehabilitation 
The patients involved in this trial are chronic respiratory patients who are expected to benefit 
from rehabilitation programs to improve their functional status. The study aims to check the 
feasibility of remotely supervised outdoor training programs based on control of walking speed 
enabled by use of the MobiHealth BAN. The physiotherapist will receive online information 
on the patient's exercise performance and will provide feedback and advice. It is expected that 
by enabling patients to perform physical training in their own local settings, the benefits, in 
terms of cost and social acceptance, can be significant. Parameters to be measured are pulse 
oximetry, ECG and mobility with audio communication between patient and remote 
supervising physiotherapist.  
4.6 Trial 6 - Sweden  
Lighthouse alarm and locator trial 
The target group involved in the trials are patients at the Lighthouse care resource centre and 
also clients living at home, but with the common characteristic that all have an alarm system 
located in their room at the Lighthouse Centre or in their home. The current system does not 
allow the patient any freedom related to mobility and forces the patient to be trapped at home 
or in their room at the Centre. By replacing the fixed alarm system with the mobile MobiHealth 
system the patient can move freely anywhere. In addition, positioning and vital signs are 
monitored and video communication is planned with UMTS .  
The effectiveness of the new GPRS/UMTS-based alarm and locating device (a variant 
of the MobiHealth BAN) will be tested according to several determining factors: safety, 
convenience, empowerment of user, mobility of user and improvement in efficiency of care 
given. 
4.7 Trial 7 - Sweden  
Physical activity and impediments to activity for women with RA 
Trial subjects will be women with Rheumatoid Arthritis. The use of the BAN together with the 
mobile communications will enable collection of a completely new kind of research data which 
will enhance the understanding of the difficulties and limitations which these patients face. The 
objective is to offer solutions that will make their lives easier. 
By this collection of data, the scarce knowledge about what factors impede normal life 
will be supplemented and quality of life of RA patients may thereby be improved. By use of 
the MobiHealth BANs, the activity of the patients will be continually monitored. Parameters 
measured include heart rate, activity level, walking distance and stride length. 
4.8 Trial 8 - Sweden  
Monitoring of vital parameters in patients with respiratory insufficiency 
The group of patients involved in the trial suffer from respiratory insufficiency due to chronic 
pulmonary diseases. These people need to be under constant medical supervision in case they 
suffer an aggravation of their condition. Besides needing regular check-ups, they are also 
dependent on oxygen therapy at home, which means oxygen delivery and close supervision. 
The use of the MobiHealth BANs is designed to enable the early detection of this group of 
diseases but also to support homecare for diagnosed patients by detecting situations where the 
patient requires intervention. The expected benefits are a reduction of the number of check-ups 
and hospitalisations needed, thus saving both time and money. Parameters measured are pulse 
rate, oxygen saturation and signals from a motion sensor (accelerometer). 
4.9 Trial 9 - Sweden 
Home care and remote consultation for recently released patients in a rural area 
Home care services and the possibility of monitoring health conditions at a distance are 
changing the way of providing care in different situations. If suitable, home-based services are 
provided and patients do not need to be in hospital, for example they are recovering from an 
intervention. By investing in home care, hospitals have been able to significantly reduce 
pressure on beds and on staff time dedicated to the kind of patients named above. This trial 
tests transmission of clinical patient data by means of the MobiHealth BAN equipment to a 
physician or a registered district nurse (RDN) from patients living in a rural, low population 
density area. The expected benefit is that this solution will reduce the number of cases where 
the patient is supposed to visit a hospital for consultation unnecessarily. 
5 Evaluation of the Trials 
During the trials different types of data is collected in view of an evaluation of the results. The 
target of the evaluation is dual: first we want to verify the state of the UMTS (and GPRS) 
infrastructure and its suitability for mobile health applications, and second we want to explore 
the added value that the MobiHealth system can bring to different healthcare domains. 
The evaluation of the trials will allow us to produce a set of suggestions to the wireless 
public network operators for the improvement, upgrade or possible modification of the 
infrastructure policies and mechanisms, so that applications like the ones developed in the 
MobiHealth project can be supported. This will be supported by concrete data indicating the 
(commercial) advantages that the operators will have in supporting m-health applications. 
Furthermore it will allow us to define a commercialisation strategy for the system and services 
developed, based on the capabilities of the network infrastructure, usefulness of the system and 
acceptance by the users. 
We must note, once more, that by no means the evaluation of the trials will be done in 
view of a clinical evaluation of the system. A clinical evaluation is out of the scope of the 
project, the main target being the evaluation of the potential for m-health value added services 
over 2.5 and 3G communications. 
At the moment of the writing of this chapter (January 2004), the trials are still ongoing 
and the evaluation was not yet completed. Nevertheless some preliminary results are available 
and will be presented in the following sections. We must however note that the results are 
preliminary and that they have not yet been analysed. Thus definitive conclusions cannot be 
(yet) drawn. 
5.1 Overview of the evaluation methodology 
The trials are evaluated using a methodology developed in the project and different aspects of 
the trials are evaluated. Specifically we evaluate the trials from the technical point of view 
(technical evaluation), the medical point of view (end-user and social evaluation) and from the 
business point of view (market evaluation). 
 
The technical evaluation focuses on the evaluation of the performance of the communication 
infrastructure used in the system. The main goal being the performance evaluation of the 
communication infrastructure, characterized in terms of: infrastructure availability, bandwidth 
characteristics, percentage of data loss / corruption, transmission delay and its variation 
(“jitter”).  
The system performance related parameters are logged at the BAN side, while the 
generated traffic is logged by the 2.5/3G network measurement system. Logs at the BAN side 
declare if there were any problem regarding getting access to the network and the process of 
transmitting the data to the BEsys. The network log reports are used to verify if any of the 
logged problems at the BAN side could have been caused by the current status of the network 
during that time. Due to different restrictions it might not be always possible to log the network 
data during the trials. In this case general statistical data will be used instead.  
In addition to the network performance the technical evaluation will also assess the 
overall system in terms of validity, accuracy and robustness of the Sensor / Actuator Service 
and application, the BAN and the intra-BAN communications, time delays etc. 
 
The performance characteristics of the MobiHealth communication infrastructure are 
derived in two ways: objective and subjective evaluation.  
The objective evaluation of the infrastructure includes active and passive 
measurements. For the active measurements an external data stream is generated (that is, we 
have no real MobiHealth data) and the performance characteristics of the communication paths 
are measured. The passive measurements will be performed in the up-and-running MobiHealth 
system so that real MobiHealth data are used. During the passive measurement phase, the 
participating operators will also perform some core-network data logging of the MobiHealth 
traffic characteristics. 
The evaluation of the passive measurements is done in 4 steps. Step 1 involves testing 
on healthy volunteers in a rest state in a controlled environment (e.g., in a hospital setting) to 
compare the readings obtained from the BAN with readings taken from conventional 
equipment, and to give a first evaluation of usability, wearability, and patient satisfaction. Step 
2 is like step 1 but the patients move around so that the effect of motion artefacts and 
wearability and functionality under more real-life circumstances can be assessed. In step 3 
healthy volunteers or low risk patients are monitored in the home environment. Step 4 involves 
monitoring of patients in ‘uncontrolled’ real life situations over extended periods of time. 
 
The subjective evaluation of the infrastructure’s performance will be done by the end-
users (healthcare professionals) who will express their perceptions of functionality and 
performance characteristics as experienced during the usage of the MobiHealth system.  
 
The end user evaluation describes the usability/acceptance of the MobiHealth Services over 
2.5/3G infrastructure and it will seek the subjective opinion of users regarding the new 
services, their usability, user interaction, satisfaction, suitability, usefulness, acceptance, 
independence and experiences. Also the question about the perception on the performance 
characteristics of the system, like: system accuracy, validity, robustness, its speed or 
availability of the service will be addressed by the professional users. End users in this project 
are defined as the patients and the health care personnel who are involved in the trials and are 
using the MobiHealth system. In some trials relatives and next of kin will be involved, for 
instance in the trial that covers homecare and remote consultation for recently released patients 
in a rural area. 
The results of the end-user evaluation are collected using diaries, questionnaires, 
interviews and some objective measurements, e.g. walking distance and step-length for 
mobility assessments. End-users evaluation results will be compared against the performance 
measurements of platform to analyse existence of expected correlations. For example, the 
receipt of a not useful poor quality ECG, which cannot be interpreted by a professional, that 
coincides with large delays and packet drops in the system indicates communication 
throughput problems. 
 
The goal of the market evaluation is to provide a reliable and meaningful set of criteria which 
will allow to make valid statements and decisions regarding the market value and potential of 
the MobiHealth system in the respective trial settings which are envisaged within the project. 
The target will be the evaluation of market, health economic and commercial potentials that 
describe the different factors and requirements which determine the future market success of 
mobile healthcare systems in general and the MobiHealth system in particular. The factors 
which are important and decisive in this context include: health political issues, existing market 
structures and processes, market players, business scenarios, value chains, potential users, 
users’ characterization (behaviour, acceptance requirements), health economic relevance, 
realization of market potentials (how much and when), barriers of entry, opportunities and 
threats.  
Nevertheless given the short duration of the project and the trials, as well as the limited 
number of participants and the technical limitations, it will be hard to draw sound conclusions 
with regard to factors like health economic relevance or users’ characterization. For these 
cases, extrapolation will be applied as far as possible to derive some possible scenarios on 
potential impacts. 
The evaluation criteria include elements like readiness of the healthcare system to adopt 
mobile services, ability to integrate respective mobile services into existing market structures 
and processes, and ability to meet user requirements and gain acceptance for the respective 
mobile services. 
5.2 Some preliminary technical evaluation results 
Although at the time of writing of this paper the trials are still on-going and the measurements 
are yet to be completed, some preliminary results regarding the performance of the UMTS and 
GPRS networks and technical issues related to MobiHealth BAN can be sketched. We present 
here some of the results from the UMTS tests and trials performed in the Netherlands using the 
Vodafone pre-commercial UMTS network. We must note however that the MobiHealth project 
is the only user of the Vodafone UMTS network in the Twente region. Thus we are running 
under the best-case environment, that is, on an empty network. 
One of the first problems that we encountered in the use of the UTMS (and GPRS) 
networks is the inverted producer-consumer roles. Public networks were designed for 
applications where the end-user is a consumer of information, i.e, a typical user will send small 
requests and will receive massive data as a response. The MobiHealth system however is based 
on the reverse model: the end-user is the producer of information and not the consumer.  The 
consequence of this reversal is that the network and terminal devices cannot support (in their 
present configuration) high bandwidth transmission emanating from the end-user. This is a 
limiting factor for the measurements that the MobiHealth system can send to the health broker. 
To enhance portability and for being compatible with the operating systems available 
on portable telephones, the MobiHealth application on the MBU was programmed in Java 
under the CLDC Java Virtual Machine [17]. As a result we have been forced to use the HTTP 
protocol for transporting vital signals. However. the current HTTP protocol implementation 
under the CLDC Java VM does not allow for persistent HTTP connections. That means that 
whenever the MBU needs to send data it must establish a new TCP/IP connection. This is very 
expensive, in terms of performance. A better option would have been for the mobile telephones 
were able to use the CDC [18] platform that allows direct access to the TCP/IP layer. 
A second issue related to the use of the HTTP protocol is the fact that every time a 
request is sent, the communication is blocked until an acknowledgment or reply is received. To 
solve this problem we used a technique called chunking [19] where multiple requests are sent 
without having to wait for a reply. However not all operators allow the use of chunking for 
their GPRS network. This eventually might cause standardization problems for services and 
applications that transmit continuous real time data over the GPRS and possibly UMTS 
During the UMTS performance tests (active measurements) we performed tests trying 
to emulate a high load of the network by running 10 simultaneous UMTS transmissions.  The 
tests (which are still on-going) indicate a performance degradation (network failure) when high 
bandwidth from 10 UMTS connections are simultaneously transmitted (form the same room, 
with each UMTS connection running from its own unique terminal). The reason for this failure 
is not clear yet we hope to have more data and information at the end of the tests.  
On the positive side we were able to confirm the stability of the Vodafone UMTS 
network in the Netherlands. Tests done with a moving station (a car roaming within the 
Enschede coverage area) allowed us to maintain a connection of at least 64Kbps (up and down 
link) crossing over cell boundaries and under different speeds. The maximum bandwidth 
available for a fixed station of 64Kbps uplink and 384 downlink is readily available and stable 
thought out the coverage area (our terminal devices – Nokia UMTS telephones – do not allow 
us to obtain higher bandwidths). 
The available data bandwidth over GPRS (and UMTS) depends on the strength of the 
signal at the user location. Although the GPRS and UMTS telephones do indicate the signal 
strength during operation, this is not the case for the PCMCIA cards integrated with the iPAQ. 
Some PCMCIA cards allow the control of the signal strength using proprietary software, but 
only during set up. During data transmission the signal strength information is not available. 
However this information is of major importance for the MobiHealth application, since it will 
allow us to estimate the available bandwidth and to control the data transmission rate 
accordingly. Currently, we have the situation that when transmitting at high bandwidth at an 
area with strong signal and we pass to an area where the signal is low, we are not able to lower 
the data transmission rate and as a result the system gets overloaded. We thus believe that the 
signal rate as well as the encoding schema used during the transmission should be available to 
the application under a standardized API for all types of GPRS/UMTS terminals, whether these 
terminals are PCMCIA cards or regular mobile phones. 
6 Conclusions 
At time of writing the MobiHealth project has been running for 20 months (since May 2002). 
In the rather short duration of the project a great many problems and challenges have been 
encountered and much progress has been made. The starting point was a vision of ubiquitous 
mobile health services based on Body Area Networks. During the project we have designed 
and prototyped a health BAN and a BAN service platform and developed services for different 
patient groups according to the requirements specified by the clinical partners. Patient trials 
have begun and evaluation data are under collection for further analysis. 
MobiHealth aims to give patients a more active role in the healthcare process while at 
the same time healthcare payers are able to manage costs more directly. The healthcare BAN 
and supporting service platform is an emerging technology that promises to support this aim. 
In a collaborative effort between healthcare professionals and technology experts nine 
trials have been defined. We expect to use these trials to evaluate the functionality and 
performance of the BAN and service platform. The main element of this evaluation will be an 
analysis of the suitability of 2.5/3G public wireless infrastructures for the support of remote 
healthcare monitoring. We intend to evaluate the social impact, user satisfaction and usability 
of the BAN on the patient and professional experience.  Trials have already started and initial 
feedback indicates that our remote healthcare monitoring system is an important technology 
that facilitates the move towards empowered managed care. 
MobiHealth has resulted in an early prototype of the BAN, engineered mainly by 
integration of existing technologies without focusing on miniaturization or optimisation of 
power consumption. The main focus has been on the architecture, design and implementation 
of an m-health service platform. The result is a first version of a service platform whose 
architecture is comprised of a set of clearly defined components.  
It should not be thought however that all problems have been overcome even with use 
of current technologies. Ambulatory monitoring is more successful for some biosignals than 
others, for example some measurements are severely disrupted by movement artefacts. Some 
monitoring equipment is still too cumbersome for ambulatory use, because of the nature of the 
equipment or because of power requirements. In the area of wireless (tele)communication 
technologies (even with 2.5 and 3G) we still suffer from limited bandwidth for some 
applications, such as those which require serving many simultaneous users with applications 
requiring high bandwidth.  
The use of BANs and wireless communications in personal healthcare systems still 
raises important challenges relating to security, integrity and privacy of data during 
transmission. This applies to both local transmission (eg. intra-BAN) and long range (eg. extra-
BAN) communications. End-to-end security and Quality of Service guarantees need to be 
implemented. Safety of hardware (eg. electrical safety, emissions, interference) and reliability 
and correctness of applications must also be a priority in deployment of mobile services. 
Comfort and convenience of sensors or BANs worn long term for continuous monitoring is 
important for usability and user acceptance. Timeliness of information availability in the face 
of unreliable performance of underlying network services is another issue. Provision of 
seamless services across regional and national boundaries multiplies these difficulties. 
Powering always on devices and continuous transmission will continue to raise technical 
challenges. Business models for healthcare and accounting and billing models for network 
services need to evolve if technical innovations are to be exploited fully. Standardisation at all 
levels is essential for open solutions to prevail. At the same time specialization, customisation 
and personalisation are widely considered to be success criteria for innovative services.  
Although our formal work in the MobiHealth project will be completed in the end of 
February of 2004, plans are underway for the creation of a venture for the further development 
and commercialisation of the results. The great interest shown by healthcare organizations and 
commercial companies, as well as the products that become available in the market every day 
and the interest shown by patients encourages us to proceed as fast as possible in the creation 
of a company that will promote and commercialise the MobiHealth services and platform. We 
expect that by the end of the 2004 to have a first version of a commercial system available to 
interested users in different European countries. 
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